Clinical trial
Effects of Pegylated Interferon Alfa-2b and Ribavirin After Orthotopic Liver…
NCT00378599 · Merck Sharp & Dohme LLC, Industry · Completed
Key facts
| NCT number | NCT00378599 |
|---|---|
| Title | Effects of Pegylated Interferon Alfa-2b and Ribavirin After Orthotopic Liver Transplantation in Subjects With Chronic Hepatitis C Recurrence (P04590AM3)(COMPLETED) |
| Official title | PROTECT - Pegylated Interferon Alfa-2b and Ribavirin After Orthotopic Liver Transplantation: Efficacy and Safety in Hepatitis C Recurrence Therapy |
| Lead sponsor | Merck Sharp & Dohme LLC, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Liver Transplantation, Hepatitis C, Chronic, Liver Cirrhosis |
| Intervention type | Drug |
| Interventions | Combination of (a) pegylated interferon alfa-2b and (b) rebetol |
| Enrollment | 125 |
| Start date | May 1, 2006 |
| Primary completion | Jul 1, 2009 |
| Completion | Jul 1, 2009 |
| First posted | Sep 20, 2006 |
| Last update posted | Apr 6, 2017 |
At a glance
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: